Publication:
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

Simple item page
dc.contributor.authorHagop M. Kantarjianen_US
dc.contributor.authorTimothy P. Hughesen_US
dc.contributor.authorRichard A. Larsonen_US
dc.contributor.authorDong Wook Kimen_US
dc.contributor.authorSurapol Issaragrisilen_US
dc.contributor.authorPhilipp le Coutreen_US
dc.contributor.authorGabriel Etienneen_US
dc.contributor.authorCarla Boquimpanien_US
dc.contributor.authorRicardo Pasquinien_US
dc.contributor.authorRichard E. Clarken_US
dc.contributor.authorViviane Dubruilleen_US
dc.contributor.authorIan W. Flinnen_US
dc.contributor.authorSlawomira Kyrcz-Krzemienen_US
dc.contributor.authorEwa Medrasen_US
dc.contributor.authorMaria Zanichellien_US
dc.contributor.authorIsrael Benditen_US
dc.contributor.authorSilvia Cacciatoreen_US
dc.contributor.authorKsenia Titorenkoen_US
dc.contributor.authorPaola Aimoneen_US
dc.contributor.authorGiuseppe Saglioen_US
dc.contributor.authorAndreas Hochhausen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherSouth Australian Health and Medical Research Instituteen_US
dc.contributor.otherSection of Hematology Oncology, The University of Chicagoen_US
dc.contributor.otherCHU de Nantesen_US
dc.contributor.otherSlaski Uniwersytet Medyczny w Katowicachen_US
dc.contributor.otherCharité – Universitätsmedizin Berlinen_US
dc.contributor.otherRoyal Liverpool University Hospitalen_US
dc.contributor.otherUniversitätsklinikum Jena und Medizinische Fakultäten_US
dc.contributor.otherSarah Cannon Research Instituteen_US
dc.contributor.otherUniversidade Federal do Paranaen_US
dc.contributor.otherUniversity of Texas MD Anderson Cancer Centeren_US
dc.contributor.otherUniversità degli Studi di Torinoen_US
dc.contributor.otherNovartis International AGen_US
dc.contributor.otherThe University of Adelaideen_US
dc.contributor.otherUniversidade de São Pauloen_US
dc.contributor.otherWroclaw Medical Universityen_US
dc.contributor.otherInstitut Bergonieen_US
dc.contributor.otherThe Catholic University of Korea, College of Medicineen_US
dc.contributor.otherNovartis Pharma LLCen_US
dc.contributor.otherOncoclínica Rio de Janeiroen_US
dc.contributor.otherHemorioen_US
dc.date.accessioned2022-08-04T08:07:54Z
dc.date.available2022-08-04T08:07:54Z
dc.date.issued2021-07-01en_US
dc.description.abstractWe found an error within Fig. 2B of the manuscript, and unfortunately this was not caught prior to submission and publication. Attached please find the corrected Fig. 2B.en_US
dc.identifier.citationLeukemia. Vol.35, No.7 (2021), 2142-2143en_US
dc.identifier.doi10.1038/s41375-021-01306-1en_US
dc.identifier.issn14765551en_US
dc.identifier.issn08876924en_US
dc.identifier.other2-s2.0-85107532351en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/76123
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85107532351&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleCorrection to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)en_US
dc.typeErratumen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85107532351&origin=inwarden_US

Files

Collections

Scopus 2021